CLOs on the Move


 
Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our multi-disciplinary research and clinical development team members, who prior to joining Kadmon had brought more than 15 drugs to market, to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing our small molecule and biologics platforms. We utilize our advanced understanding of the molecular mechanisms of disease to ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.kadmon.com
  • 450 East 29th Street
    New York, NY USA 10016
  • Phone: 212.308.6000

Executives

Name Title Contact Details
Steven Gordon
Executive Vice President, General Counsel, Chief Administrative, Compliance and Legal Officer, and Corporate Secretary Profile
Gregory Moss
Executive Vice President, General Counsel and Corporate Secretary Profile
Gregory Moss
Executive Vice President, General Counsel and Corporate Secretary Profile

Similar Companies

Celcuity

Celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform.

Ambrx

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.

Linden Labs

Linden Labs is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

InVitria

InVitria is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Shoreline Biosciences

Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms. The company`s cellular design technologies are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including iNK cells and iMACs as allogeneic "off-the-shelf" cellular immunotherapies designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA.